Evidence map›Paper›PMID 41347093›Full record

ArticleFrontiers in oncology2025

CMSP suppresses oral squamous cell carcinoma progression by targeting the JAK2/STAT3/c-Myc axis.

Yueting Lu, Manman Yao, Dixian Wang, Daisuke Higuchi, Hualin Lu, Hongyue Shang, Bo Dong, Jiao Zhang, Ruizhe Jin, Tiejun Liu

Abstract read
In one paragraph

Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yueting Lu *Department of Stomatology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Manman YaoDepartment of Stomatology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Dixian Wang *Department of Stomatology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Daisuke HiguchiDepartment of Prosthodontics, Matsumoto Dental University, Matsumoto, Japan.
Hualin LuDepartment of Stomatology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Hongyue ShangDepartment of Stomatology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Bo DongDepartment of Stomatology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Jiao ZhangDepartment of Stomatology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Ruizhe JinDepartment of Stomatology, Hebei Children's Hospital, Shijiazhuang, Hebei, China.
Tiejun LiuDepartment of Stomatology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Oral squamous cell carcinoma (OSCC) is a highly invasive head and neck malignancy with poor prognosis and limited treatment efficacy. This study aimed to investigate the anti-tumor potential of p-hydroxycinnamaldehyde (CMSP), a bioactive compound derived from the traditional Chinese and Mongolian medicinal herb Momordica cochinchinensis. Methods: The effects of CMSP on OSCC were evaluated in vitro using CAL27 and SCC15 cell lines and in vivo in a CAL27 xenograft nude mouse model. Cell proliferation, migration, and invasion were assessed by CCK-8 and transwell assays. Flow cytometry was used to analyze cell cycle and apoptosis. Transcriptomic sequencing followed by KEGG and GO enrichment analyses was performed to identify key regulatory pathways, and Western blotting was used to validate protein expression. Bioinformatics and molecular docking analyses were further conducted to explore CMSP-target interactions. Results: CMSP inhibited proliferation, migration, and invasion of OSCC cells in a dose-dependent manner, induced S-phase arrest, and promoted apoptosis. Transcriptomic and enrichment analyses identified the JAK2/STAT3 signaling pathway as a major target. Western blotting confirmed that CMSP significantly suppressed phosphorylation of JAK2 and STAT3 and downregulated downstream c-Myc expression. In vivo, CMSP markedly reduced tumor growth in nude mice. Bioinformatics and molecular docking suggested that MYC-related signaling contributes to the anti-tumor activity of CMSP in OSCC. Conclusion: CMSP exerts anti-OSCC effects, at least in part, through modulation of the JAK2/STAT3/c-Myc signaling axis, and may serve as a promising adjunctive therapeutic candidate for OSCC management.

Indexed as

apoptosisepithelial-mesenchymal transitionJAK2/STAT3/c-Myc signaling pathwayoral squamous cell carcinomap-hydroxycinnamaldehydetranscriptome sequencingtumor immune microenvironment

Identifiers

PMID41347093
PMCPMC12672324

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.